The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer

Kwang Dae Hong, Sun Il Lee, Hong Young Moon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: The aim of this study was to evaluate the impact on disease-free survival (DFS) of adding oral tegafur-uracil (UFT) to intravenous 5-fluorouracil (5-FU) as surgical adjuvant chemotherapy for stage II and III colon cancer. Methodology: The authors retrospectively analyzed 148 patients treated from 2000 through 2005 with pathologically confirmed stage II or III colon cancer. Forty seven patients were treated with 6 cycles of 5-FU+leucovorin (5-FU group) and the other 101 patients were treated with same above regimen followed by an additional 12 cycles of UFT+leucovorin (LV) for 28 days with a 7-day rest period (5-FU+UFT group). Results: The median follow-up time was 64.9 months (range 15.3-95.2 months) and mean age was 58.8±10.8. The clinical characteristics of the 5-FU+UFT and 5-FU groups were similar. Furthermore, for all study subjects and stage II patients, 3-year DFS rates were not significantly different between two groups. However, for stage III patients, 3-year DFS rates were 80.0% and 60.7% in the 5-FU+UFT and 5-FU groups, respectively (HR=0.32; p=0.01; 95% CI=0.13-0.76). Conclusions: The addition of UFT to 5-FU was found that significantly improve DFS in patients with stage III colon cancer. The authors cautiously suggest UFT as a maintenance therapy following 5-FU chemotherapy could be another option in stage III colon cancer patients.

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalHepato-Gastroenterology
Volume59
Issue number113
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Tegafur
Uracil
Fluorouracil
Colonic Neoplasms
Drug Therapy
Disease-Free Survival
Therapeutics
Leucovorin
Survival Rate
Adjuvant Chemotherapy

Keywords

  • Adjuvant chemotherapy
  • Colon cancer
  • Fluorouracil
  • Tegafur-uracil

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

@article{f10305f2def1455e8e31850d650781ad,
title = "The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer",
abstract = "Background/Aims: The aim of this study was to evaluate the impact on disease-free survival (DFS) of adding oral tegafur-uracil (UFT) to intravenous 5-fluorouracil (5-FU) as surgical adjuvant chemotherapy for stage II and III colon cancer. Methodology: The authors retrospectively analyzed 148 patients treated from 2000 through 2005 with pathologically confirmed stage II or III colon cancer. Forty seven patients were treated with 6 cycles of 5-FU+leucovorin (5-FU group) and the other 101 patients were treated with same above regimen followed by an additional 12 cycles of UFT+leucovorin (LV) for 28 days with a 7-day rest period (5-FU+UFT group). Results: The median follow-up time was 64.9 months (range 15.3-95.2 months) and mean age was 58.8±10.8. The clinical characteristics of the 5-FU+UFT and 5-FU groups were similar. Furthermore, for all study subjects and stage II patients, 3-year DFS rates were not significantly different between two groups. However, for stage III patients, 3-year DFS rates were 80.0{\%} and 60.7{\%} in the 5-FU+UFT and 5-FU groups, respectively (HR=0.32; p=0.01; 95{\%} CI=0.13-0.76). Conclusions: The addition of UFT to 5-FU was found that significantly improve DFS in patients with stage III colon cancer. The authors cautiously suggest UFT as a maintenance therapy following 5-FU chemotherapy could be another option in stage III colon cancer patients.",
keywords = "Adjuvant chemotherapy, Colon cancer, Fluorouracil, Tegafur-uracil",
author = "Hong, {Kwang Dae} and Lee, {Sun Il} and Moon, {Hong Young}",
year = "2012",
month = "1",
day = "1",
doi = "10.5754/hge10419",
language = "English",
volume = "59",
pages = "104--107",
journal = "Hepato-Gastroenterology",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "113",

}

TY - JOUR

T1 - The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer

AU - Hong, Kwang Dae

AU - Lee, Sun Il

AU - Moon, Hong Young

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background/Aims: The aim of this study was to evaluate the impact on disease-free survival (DFS) of adding oral tegafur-uracil (UFT) to intravenous 5-fluorouracil (5-FU) as surgical adjuvant chemotherapy for stage II and III colon cancer. Methodology: The authors retrospectively analyzed 148 patients treated from 2000 through 2005 with pathologically confirmed stage II or III colon cancer. Forty seven patients were treated with 6 cycles of 5-FU+leucovorin (5-FU group) and the other 101 patients were treated with same above regimen followed by an additional 12 cycles of UFT+leucovorin (LV) for 28 days with a 7-day rest period (5-FU+UFT group). Results: The median follow-up time was 64.9 months (range 15.3-95.2 months) and mean age was 58.8±10.8. The clinical characteristics of the 5-FU+UFT and 5-FU groups were similar. Furthermore, for all study subjects and stage II patients, 3-year DFS rates were not significantly different between two groups. However, for stage III patients, 3-year DFS rates were 80.0% and 60.7% in the 5-FU+UFT and 5-FU groups, respectively (HR=0.32; p=0.01; 95% CI=0.13-0.76). Conclusions: The addition of UFT to 5-FU was found that significantly improve DFS in patients with stage III colon cancer. The authors cautiously suggest UFT as a maintenance therapy following 5-FU chemotherapy could be another option in stage III colon cancer patients.

AB - Background/Aims: The aim of this study was to evaluate the impact on disease-free survival (DFS) of adding oral tegafur-uracil (UFT) to intravenous 5-fluorouracil (5-FU) as surgical adjuvant chemotherapy for stage II and III colon cancer. Methodology: The authors retrospectively analyzed 148 patients treated from 2000 through 2005 with pathologically confirmed stage II or III colon cancer. Forty seven patients were treated with 6 cycles of 5-FU+leucovorin (5-FU group) and the other 101 patients were treated with same above regimen followed by an additional 12 cycles of UFT+leucovorin (LV) for 28 days with a 7-day rest period (5-FU+UFT group). Results: The median follow-up time was 64.9 months (range 15.3-95.2 months) and mean age was 58.8±10.8. The clinical characteristics of the 5-FU+UFT and 5-FU groups were similar. Furthermore, for all study subjects and stage II patients, 3-year DFS rates were not significantly different between two groups. However, for stage III patients, 3-year DFS rates were 80.0% and 60.7% in the 5-FU+UFT and 5-FU groups, respectively (HR=0.32; p=0.01; 95% CI=0.13-0.76). Conclusions: The addition of UFT to 5-FU was found that significantly improve DFS in patients with stage III colon cancer. The authors cautiously suggest UFT as a maintenance therapy following 5-FU chemotherapy could be another option in stage III colon cancer patients.

KW - Adjuvant chemotherapy

KW - Colon cancer

KW - Fluorouracil

KW - Tegafur-uracil

UR - http://www.scopus.com/inward/record.url?scp=84863251048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863251048&partnerID=8YFLogxK

U2 - 10.5754/hge10419

DO - 10.5754/hge10419

M3 - Article

C2 - 22251527

AN - SCOPUS:84863251048

VL - 59

SP - 104

EP - 107

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

SN - 0172-6390

IS - 113

ER -